北海康成-B(01228.HK)訂立基因療法業務合約
北海康成-B(01228.HK)公布與康成諾愛(蘇州)生物科技於2022年6月10日訂立合約安排,以取得可變利益實體的經濟利益及控制權。
可變利益實體將從事涉及基因療法及相關產品的研究、開發及商業化的業務,根據外商投資法,該等業務屬於中國負面清單的「禁止」類別。截至公告日期,集團尚未於中國開展基因療法解決方案業務。
透過合約安排,外商獨資企業將對可變利益實體的財務及營運擁有實際控制權,並將享有可變利益實體產生的經濟利益及利益。於訂立合約安排後,可變利益實體的財務業績將併入集團的綜合財務報表,而可變利益實體將成為公司的間接非全資附屬公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.